川芎嗪注射液联合依托泊苷和顺铂(EP)方案治疗小细胞肺癌的临床疗效及对血清白细胞介素-15、N末端脑钠肽前体水平的影响

Clinical Efficacy of Ligustrazine Injection Combined with Etoposide and Cisplatin(EP)Regimen in The Treatment Of Small Cell Lung Cancer And Its Effect On Serum IL-15 And NT-Probnp Levels

目的观察川芎嗪注射液联合EP方案治疗小细胞肺癌(Small cell lung cancer,SCLC)的临床疗效及对血清白细胞介素-15(Interleukin,IL-15)、N末端脑钠肽前体(N-terminal pro brain natriuretic peptide,NT-proBNP)水平的影响。方法选取2016年5月—2019年8月期间武警山东省总队医院收治的SCLC患者205例,按照随机数字表法分为对照组102例和治疗组103例。对照组患者接受单纯EP方案治疗,治疗组患者则采取川芎嗪注射液联合EP方案治疗。治疗6个疗程后,观察比较两组患者近远期疗效、生活质量、血清IL-15和NT-proBNP水平变化以及不良反应等情况。结果治疗后治疗组肿瘤客观总有效率为71.84%(74/103),对照组总有效率为57.84%(59/102),治疗组总有效率明显高于对照组,差异有统计学意义(P<0.05)。治疗后治疗组生活质量总有效率为92.23%(95/103),对照组总有效率为81.37%(83/102),治疗组生活质量总有效率明显高于对照组81.37%,差异有统计学意义(P<0.05)。治疗后两组患者1年的生存率比较,差异无统计学意义(P>0.05);治疗组2、3年的生存率高于对照组,差异有统计学意义(P<0.05)。治疗后两组患者血清IL-15、NT-proBNP水平较较治疗前下降,差异有统计学意义(P<0.05);且治疗组均较对照组明显降低,差异有统计学意义(P<0.05)。治疗组不良反应发生率13.59%(14/103),低于对照组31.37%(32/102),差异有统计学意义(P<0.05)。结论川芎嗪注射液联合EP方案治疗SCLC的临床疗效确切,可提高SCLC患者的生活质量及生存率,改善其血清IL-15、NT-proBNP水平,减少不良反应的发生。

Objective To observe the clinical efficacy of ligustrazine injection combined with EP regimen in the treatment of small cell lung cancer(SCLC)and its impact on the level of serum interleukin-15(IL-15)and N-terminal pro-brain natriuretic peptide(NT-proBNP).Methods From May 2016 to August 2019,205 SCLC patients admitted to the Shandong Provincial Corps Hospital of the Armed Police were selected and divided into a control group of 102 cases and a treatment group of 103 cases according to the random table method.The patients in the control group were treated with EP alone,while the patients in the treatment group were treated with ligustrazine injection combined with EP.After 6 courses of treatment,the short-term and long-term efficacy,quality of life,serum IL-15 and NT-proBNP levels,and adverse reactions were observed and compared between the two groups.Results After treatment,the objective total effective rate of tumor in the treatment group was 71.84%(74/103),and the total effective rate in the control group was 57.84%(59/102).The total effective rate in the treatment group was significantly higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the total effective rate of quality of life in the treatment group was 92.23%(95/103),and the total effective rate in the control group was 81.37%(83/102).Academic significance(P<0.05).There was no significant difference in the one-year survival rate between the two groups after treatment(P>0.05);the 2-and 3-year survival rate in the treatment group was higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of serum IL-15 and NT-proBNP in the two groups were lower than those before treatment,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the treatment group was 13.59%(14/103),which was lower than 31.37%(32/102)in the control group,and the difference was statistically significant(P<0.05).Conclusion Ligustrazine injection combined with EP regimen has a definite clinical efficacy in the treatment of SCLC.It can improve the quality of life and survival rate of SCLC patients,improve their serum IL-15 and NT-proBNP levels,and reduce the occurrence of adverse reactions.